Literature DB >> 21880639

Follicular lymphoma grade 3B: is it a real disease?

Nancy Lee Harris, Philip Kluin.   

Abstract

Entities:  

Mesh：

Year:  2011        PMID： 21880639      PMCID： PMC3166091          DOI： 10.3324/haematol.2011.050930

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  23 in total

1.  A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survival.

Authors:  Christine P Hans; Dennis D Weisenburger; Julie M Vose; Lynette M Hock; James C Lynch; Patricia Aoun; Timothy C Greiner; Wing C Chan; Robert G Bociek; Philip J Bierman; James O Armitage
Journal:  Blood       Date:  2002-11-07       Impact factor: 22.113

2.  Cytogenetic alterations affecting BCL6 are predominantly found in follicular lymphomas grade 3B with a diffuse large B-cell component.

Authors:  Tiemo Katzenberger; German Ott; Thomas Klein; Jörg Kalla; Hans Konrad Müller-Hermelink; M Michaela Ott
Journal:  Am J Pathol       Date:  2004-08       Impact factor: 4.307

3.  Low histologic grade follicular lymphoma with high proliferation index: morphologic and clinical features.

Authors:  Sa A Wang; Lan Wang; Ephraim P Hochberg; Alona Muzikansky; Nancy Lee Harris; Robert P Hasserjian
Journal:  Am J Surg Pathol       Date:  2005-11       Impact factor: 6.394

4.  Low-grade follicular lymphoma with t(14;18) presents a homogeneous disease entity otherwise the rest comprises minor groups of heterogeneous disease entities with Bcl2 amplification, Bcl6 translocation or other gene aberrances.

Authors:  Y Guo; K Karube; R Kawano; T Yamaguchi; J Suzumiya; G-S Huang; K Ohshima
Journal:  Leukemia       Date:  2005-06       Impact factor: 11.528

5.  Molecular, cytogenetic, and immunophenotypic characterization of follicular lymphoma grade 3B; a separate entity or part of the spectrum of diffuse large B-cell lymphoma or follicular lymphoma?

Authors:  Anneke G Bosga-Bouwer; Anke van den Berg; Eugenia Haralambieva; Debora de Jong; Ronald Boonstra; Philip Kluin; Eva van den Berg; Sibrand Poppema
Journal:  Hum Pathol       Date:  2006-05       Impact factor: 3.466

6.  Updated Kiel classification for lymphomas.

Authors:  D H Wright
Journal:  J Pathol       Date:  1989-04       Impact factor: 7.996

7.  Criteria for the cytologic subclassification of follicular lymphomas: a proposed alternative method.

Authors:  R B Mann; C W Berard
Journal:  Hematol Oncol       Date:  1983 Apr-Jun       Impact factor: 5.271

8.  Patients with grade 3 follicular lymphoma have prolonged relapse-free survival following anthracycline-based chemotherapy: the Nebraska Lymphoma Study Group Experience.

Authors:  A K Ganti; D D Weisenburger; L M Smith; C P Hans; R G Bociek; P J Bierman; J M Vose; J O Armitage
Journal:  Ann Oncol       Date:  2006-03-08       Impact factor: 32.976

9.  Follicular lymphoma grade 3B includes 3 cytogenetically defined subgroups with primary t(14;18), 3q27, or other translocations: t(14;18) and 3q27 are mutually exclusive.

Authors:  Anneke G Bosga-Bouwer; Gustaaf W van Imhoff; Ronald Boonstra; Anneke van der Veen; Eugenia Haralambieva; Anke van den Berg; Bauke de Jong; Vanessa Krause; Martin C Palmer; Robert Coupland; Philip M Kluin; Eva van den Berg; Sibrand Poppema
Journal:  Blood       Date:  2003-02-01       Impact factor: 22.113

10.  Prognostic value of cellular proliferation and histologic grade in follicular lymphoma.

Authors:  A R Martin; D D Weisenburger; W C Chan; E I Ruby; J R Anderson; J M Vose; P J Bierman; M A Bast; D T Daley; J O Armitage
Journal:  Blood       Date:  1995-06-15       Impact factor: 22.113
View more
  2 in total

1.  Follicular lymphomas: a tapestry of common and contrasting threads.

Authors:  Elaine S Jaffe
Journal:  Haematologica       Date:  2013-08       Impact factor: 9.941

Review 2.  Recommendations for Clinical Trial Development in Follicular Lymphoma.

Authors:  Kami Maddocks; Paul M Barr; Bruce D Cheson; Richard F Little; Lawrence Baizer; Brad S Kahl; John P Leonard; Nathan Fowler; Leo I Gordon; Brian K Link; Jonathan W Friedberg; Stephen M Ansell
Journal:  J Natl Cancer Inst       Date:  2016-12-31       Impact factor: 13.506
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.